In a pharmaceutical supply chain defined by disruption, the quality of a partnership can matter as much as the quality of the product. Paula Pulsoni, vice-president of service development and innovation at World Courier, says companies that want stronger supplier relationships need to recognise first how much their own scale, structure and maturity shape what is possible. In an environment where volatility is now routine, she argues that organisations cannot wait for a crisis before d...
Continue Reading This Article
Enjoy this article as well as all of our content, including reports, news, tips and more.
By registering or signing into your SRM Today account, you agree to SRM Today's Terms of Use and consent to the processing of your personal information as described in our Privacy Policy.
eciding whether a relationship is resilient enough to cope.
That point is echoed by wider industry thinking. McKinsey has argued that pharmaceutical supplier relationships are moving away from purely transactional arrangements and towards strategic collaborations built around shared goals, governance and transparency. The consultancy says successful partnerships increasingly depend on strong procurement capability, close alignment between business teams and procurement, committed leadership and the ability to integrate technology effectively.
Pulsoni’s focus is less on theory than on operating discipline. She says organisations need clear governance and regular communication rhythms so they can judge whether a partnership is genuinely ready for disruption, rather than merely sounding collaborative on paper. For pharmaceutical companies, that can mean establishing expectations early, defining responsibilities and reviewing whether the relationship can withstand supply shocks, regulatory pressure or changes in demand.
The same logic applies inside companies as well as between them. Pulsoni points to internal alignment as a decisive factor, especially when a partnership crosses functions and becomes part of a broader business priority such as sustainability. In those situations, procurement is not just a buying function but a translator, helping different departments understand the purpose of the partnership, the resources it will require and the compromises it may involve.
Research on pharmaceutical supply chains supports that emphasis on trust and information-sharing. A study published in the National Library of Medicine found that culture, cooperation, coordination and open exchange of information are central to creating safe and durable supply chain relationships. It concluded that trust is not a soft extra but a practical condition for long-term collaboration.
McKinsey has also warned that partnerships often fail when senior leaders are not fully engaged, resources are thin or incentives are misaligned. In practice, that means even well-intentioned alliances can stall if the organisations involved are not prepared to commit the time, attention and discipline needed to make collaboration work.
The same themes are increasingly visible in sponsor-CDMO relationships, where PharmaSource says global disruption and changing regulatory expectations are pushing companies to treat external manufacturing partners as strategic allies rather than interchangeable vendors. It identifies trust, transparency, reliability and a shared horizon for growth as the foundations of stronger working relationships.
For Pulsoni, the lesson is ultimately simple: resilient supply chains are built through consistency, not slogans. Face-to-face contact still matters, communication has to be regular, and both sides need to stay anchored to the patient, who remains the real beneficiary when supplier relationships are strong enough to withstand pressure.
Source: Noah Wire Services
